Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Peter C. Fong"'
Autor:
Ana Oaknin, Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Andrew Dean, Nicoletta Colombo, Johanne I. Weberpals, Andrew R. Clamp, Giovanni Scambia, Alexandra Leary, Robert W. Holloway, Margarita Amenedo Gancedo, Peter C. Fong, Jeffrey C. Goh, David M. O’Malley, Deborah K. Armstrong, Susana Banerjee, Jesus García‐Donas, Elizabeth M. Swisher, Terri Cameron, Lara Maloney, Sandra Goble, Jonathan A. Ledermann, Robert L. Coleman
Publikováno v:
Cancer Medicine, Vol 10, Iss 20, Pp 7162-7173 (2021)
Abstract Background The efficacy and safety of rucaparib maintenance treatment in ARIEL3 were evaluated in subgroups based on best response to most recent platinum‐based chemotherapy and baseline disease. Methods Patients were randomized 2:1 to rec
Externí odkaz:
https://doaj.org/article/2cbcf9c399a94021b6832bbcf96e807d
MicroRNA profiling of ovarian granulosa cell tumours reveals novel diagnostic and prognostic markers
Autor:
Wei-Tzu Cheng, Roseanne Rosario, Anita Muthukaruppan, Michelle K Wilson, Kathryn Payne, Peter C. Fong, Andrew N. Shelling, Cherie Blenkiron
Publikováno v:
Clinical Epigenetics, Vol 9, Iss 1, Pp 1-10 (2017)
Abstract Background The aim of this study was to explore the clinical utility of microRNAs (miRNAs) as improved markers of ovarian granulosa cell tumours (GCTs) for cancer diagnosis and prognosis prediction. Current histopathological and genetic mark
Externí odkaz:
https://doaj.org/article/c2aec7e0385e4f5ba350ebf5d714dd5d
Autor:
David M. O'Malley, Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I. Weberpals, Andrew R. Clamp, Giovanni Scambia, Alexandra Leary, Robert W. Holloway, Margarita Amenedo Gancedo, Peter C. Fong, Jeffrey C. Goh, Elizabeth M. Swisher, Lara Maloney, Sandra Goble, Kevin K. Lin, Tanya Kwan, Jonathan A. Ledermann, Robert L. Coleman
Objective: ARIEL3 (NCT01968213) is a placebo-controlled randomized trial of the poly(ADP-ribose) polymerase inhibitor rucaparib as maintenance treatment in patients with recurrent high-grade ovarian carcinoma who responded to their latest line of pla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14c846a37be8f0961b89c3e8a59cc1db
https://hdl.handle.net/10281/403099
https://hdl.handle.net/10281/403099
Autor:
Petros Grivas, Evgeny Kopyltsov, Po-Jung Su, Francis X. Parnis, Se Hoon Park, Yoshiaki Yamamoto, Peter C. Fong, Christophe Tournigand, Miguel A. Climent Duran, Aristotelis Bamias, Claudia Caserta, Jane Chang, Paul Cislo, Alessandra di Pietro, Jing Wang, Thomas Powles
Publikováno v:
European urology.
In JAVELIN Bladder 100, avelumab first-line maintenance plus best supportive care (BSC) significantly prolonged overall survival (OS; primary endpoint) versus BSC alone in patients with advanced urothelial carcinoma (aUC) without disease progression
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b07019f2c308a17c0ae2b597f178c80b
https://pubmed.ncbi.nlm.nih.gov/35654659
https://pubmed.ncbi.nlm.nih.gov/35654659